ArticleBMC geriatrics2026
Prevalence of frailty, multimorbidity, and polypharmacy and their association with health outcomes in hospitalized older adults: a prospective multicenter cohort study.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe growing burden of frailty, multimorbidity, and polypharmacy among older adults presents major challenges to healthcare systems worldwide. These interrelated conditions are known to worsen clinical outcomes, yet data from the region are limited. This study aimed to examine the prevalence and clinical impact of frailty, complex multimorbidity, and polypharmacy among hospitalized older adults in Oman.
methodsA prospective, multicenter cohort study was conducted in general internal medicine wards of two tertiary hospitals in Oman. Patients aged ≥ 65 years were consecutively enrolled and assessed for frailty using Clinical Frailty Scale (CFS), multimorbidity using the Charlson Comorbidity Index (CCI) and a definition of complex multimorbidity (≥ 3 chronic conditions), and polypharmacy (≥ 5 medications). Clinical outcomes included hospital length of stay (LOS), in-hospital mortality, HD/ICU admission, 30- and 90-day mortality, and 30- and 90-day readmission. Multivariable regression and Kaplan-Meier survival analyses were used.
resultsAmong 369 patients, high frailty, complex multimorbidity, and polypharmacy were present in 139 (37.67%), 126 (34.15%), and 243 (65.85%) patients, respectively. Higher frailty was associated with longer LOS (6.49 vs. 4.88 days, p < 0.01) and increased in-hospital mortality (15.11% vs. 3.54%, p < 0.01). High frailty independently predicted 30-day mortality (adjusted odds ratio [aOR] 5.68, p < 0.01) and 90-day mortality (aOR 3.53, p < 0.01). Complex multimorbidity independently predicted 30-day readmission (aOR 1.92, p = 0.015), 30-day mortality (aOR 2.12, p = 0.026), and 90-day mortality (aOR 2.42, p < 0.01). Kaplan-Meier and adjusted Cox regression analyses showed lower 90-day survival and higher mortality risk among patients with high frailty (adjusted hazard ratio [aHR] 3.16, 95% CI 1.69-5.89, p < 0.001) and complex multimorbidity (aHR 1.85, 95% CI 1.15-2.98, p = 0.011).
conclusionFrailty, complex multimorbidity, and polypharmacy were common among hospitalized older adults in Oman. High frailty and complex multimorbidity were the most consistent predictors of adverse outcomes, supporting early recognition, structured geriatric assessment pathways, and future targeted patient-centered interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.